Additionally, Gamitrinib could reverse Bcl2-mediated resistance in Hep3B cells[52], and it could also work synergistically with Bcl-2 inhibitors, including ABT263, obatoclax, ABT199, WEHI-539, and A1210477 in a panel of therapy-resistant tumors in vitro and in vivo in murine model systems of melanoma, triple-negative breast cancer (TNBC), and patient-derived orthotopic xenografts (PDX) of human glioblastoma[53]. Here, BCL2 is linked to triple-negative breast carcinoma.